Podcasts about CSL

The ASX 200 slid a mere 3 points to 8846 as the US government shutdown weighed on sentiment. BHP under pressure from the off on news of a halt to iron ore sales in China, falling 2.5% with RIO up 0.5% and FMG doing well, up 1.4%. Lithium stocks under pressure on CATL news of a reopening, MIN fell 3.8%, LTR off 10.7% and PLS falling 6.4%. Copper stocks mixed, SFR up 1.6% and gold miners mostly firm, new record highs for bullion. NST up 0.8%, GMD up 0.7% and WGX rising 10.7% on its 3-year plan. Uranium eased and oil and gas mixed, STO up 0.5%. Banks eased back slightly, CBA up 0.1% with the Big Bank Basket down to $283.09 (-0.1%). Financials found some friends, SOL up 5.4% and MPL rising 0.6%. Healthcare better, CSL up 0.3% and RMD rising 0.8%. Industrials mixed, BXB up 1.3% with TLS rebounding 0.6%. Retail stocks eased a little, tech mixed, WTC up 0.6% and XRO up 0.6%. In corporate news, BVS soared 18.2% on guidance improving. APE in a trading halt pending a capital raise and a Canadian acquisition. ASB jumped 5.8% on a US Naval agreement.On the economic front, nothing locally. Asian markets muted as China National Day takes precedence. Japan down 1%.10-year yields drifted higher to 4.35%. US Futures down 0.5% on shutdown.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 gave up early gains to close down 14 points at 8849 (0.2%). Banks eased back with CBA down % and ANZ falling % as the Big Bank Basket dropped to $283.23 (-0.6%). Insurers gave back yesterday's gains. QBE down 0.7% and SUN off 0.8%. Other financials also eased slightly. REITS rose, GMG though fell 0.8%. In the industrials, TLS dropped another 1.4% and tech was mixed, WTC down another 3.0%. XRO finally finding some friends. Up 0.1%. Healthcare mixed as CSL flat after CFO retired. In resources, copper and gold continue to dominate, BHP and RIO had good days up 1.5% and 0.6% respectively. Gold once again shone bright, NST up 1.2% and EVN rising %. NEM is in for a C-Suite change and fell 2.3%. Base metal and copper stocks doing well again. Oil and gas falling hard on crude prices, WDS down 1.7% and STO off 2.5%. Nothing much happening in uranium stocks. In corporate news, SWM and SXL are set to merge. RBD up 59.3% on a takeover approach. And SGR rose 1.1% after it finalised a deal with its lenders.On the economic front, the RBA left rates unchanged. Bullock said ‘we're close' to getting economy back in balance. But we need to be cautious about inflation. Chinese PMI came in below forecasts. Asian markets mixed, China up 0.3%, HK up 0.3% - Japan down 0.2% on PM uncertainty.10-year yields steady at 4.34%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Pharma stocks plunge as Trump’s 100% tariffs send shockwaves across Asia. Hosted by Michelle Martin, we break down the impact on Singapore’s $4 billion pharma exports, Sumitomo Pharma, CSL, and more. Are these tariffs a short-term blow or a long-term reset for Asian healthcare investments? Plus, we spotlight Mapletree’s three Singapore REITs - Logistics, Industrial, and Pan-Asia Commercial - amid expected rate cuts. Which one offers the best dividend yield and growth potential? Dividend Titan’s Willie Keng shares his strategy for navigating healthcare risks and REIT opportunities. See omnystudio.com/listener for privacy information.

The ASX 200 kickstarted the week in style up 75 points to 8863 (0.9%). Gold was once again leading the charge as it pushed through US$3800, NST up 3.1% and NEM rising 4.0%. EVN also turned in a good day up 4.4%. Iron ore miners were a little floppy on steel demand in China and looming 7 -day holiday. FMG fell 2.1%. Copper and other base metal stock continue to push higher, 29M up 4.8% and MLX up 4.1%. Rare earth stocks saw profit taking, ILU down 3.9% and LYC modestly off. Energy stocks saw sellers, KAR down 1.7% and PDN falling 2.4% with WHC off 3.4%.Banks were firm today ahead of the RBA.  CBA soaring 2.2% with WBC up 2.0%. MQG recovered 1.3% with other wealth managers also better, NWL up 2.1% and insurers rallied, QBE up 1.6% and IAG up 1.3%. Healthcare was firm as CSL traded 2.5% higher on tariff hopes, RMD up 1.2% and MSB up 0.8%. REITs lacklustre, tech eased back in places, WTC down 1.2% and TNE up 1.5%. Retailers were flat, APE off 0.6% and SUL down another 1.0%. ALL a bright spot up 2.0%. In corporate news, MIN was down 0.8% on haul road news, SM1 up 10.4% on the sale of its North Island assets, and BVS rose 2.5% on a new CEO. Nothing on the economic front, RBA tomorrow. Asian markets mixed, China up 2.1% Japan down 1% on PM uncertainty.10-year yields easing to 4.34%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Ep. 331 Hope and Resilience - Rev. Sue MillerBorn From the Sunday Service at the Center for Spiritual Living in Redding on 9-28-25

Tensions are high after NATO Secretary-General Mark Rutte warned Russia that its warplanes could be shot down if they stray over European territory, a stance backed by Donald Trump. Meanwhile, Trump has imposed a 100 per cent tariff on foreign-made pharmaceutical products.See omnystudio.com/listener for privacy information.

The ASX200 closed modestly higher on Friday, up about 0.08% and breaking a three‑week losing streak, while September remains down roughly 2%. Stronger‑than‑expected August inflation trimmed market expectations for a November RBA rate cut to about 50%. US President Trump’s 100% tariff on pharma imports dragged healthcare stocks such as CSL, Pro Medicus and Mesoblast lower, whereas miners (+0.7%) and financials (+0.5%) buoyed the index, led by BHP’s 1.3% gain. Looking ahead, investors will watch the RBA’s October decision, US inflation figures and upcoming US jobs data, plus the rollout of pharma tariffs on October 1. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

The ASX 200 finished the week up 15 points to 8788 in range bound trade. Up 15 points for the week! PCE tonight in the US. Banks firmed with the Big Bank Basket up to $279.52(+0.7%). CBA up 0.7% with insurers better too, QBE up 1.2% and SUN rising 1.5%. REITs still under some pressure. GMG down 0.9%. Wealth managers still struggling from recent fund failure pessimism. HUB down 4.2% and NWL off 2.9%. Industrials generally becalmed, TCL down 0.9% with CPU down 1.8% and SGH falling 0.5%. ORG fell 2.7% with tech struggling. The All-Tech Index down 0.6%.Resources were once again the place to be. Maybe not the leaders, but the second tier was on a tear. DTR up another 17.5% with VUL doing well on a new German geo-thermal deal, up 15.6%. Gold miners rose, WGX up 2.9% and GGP rising 0.4%. NST up 0.4% as Goldfields sold down. Copper stocks were also strong, AIS up 13.1%. Few buyers creeping back in to uranium, NXG up 3.1% and DYL up 1.5%. Oil and gas stocks eased slightly.In corporate news, CSL fell hard early on tariff news, it did rally from lows, down 1.9% at the close. MSB said no effect from tariffs. Still fell 3.6%. GOR is no longer as Goldfields wraps up its acquisition. IPX rallied hard on a new US government contract. Up 6.1%.On the economic front, nothing locally. All eyes on the RBA next week. No change expected.In Asian markets, Japan down 0.6%, China off 0.3% and HK off 0.4%.10-year yields pushing higher to 4.39%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 has finished the day down 81 points or 0.9%. Ending on the session low as the midday inflation linked sell-off continued into the close. Financials worst as yesterday's Big Four rally evaporated. Banks down between 1.4% and 3.2%. MQG down 1.8%. Insurers escaped, most flat. Stock market stocks mixed but mostly down. GQG flat. PTM -2.1%. HUB -3%. Health Care, Discretionary Stocks and Tech stayed under pressure. CSL down 1.3%. PME and TLX reversing strong sessions yesterday. Both down over 3%. No major damage in Discretionary names as the prospect of even one rate cut was slightly dampened. JBH and HVN only down around 1%. GYG worst down 3.1%. WTC worst of the tech names. Failing to recover from its results drop. TNE best up 1.2% on positive broker commentary. CDA also in the green as defence stocks rose. DRO now up over 13% in two days.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Ep. 330 Listening to Spirit - Rev. Sue MillerBorn From the Sunday Service at the Center for Spiritual Living in Redding on 9-21-25

Australian shares extended losses on Thursday, with the ASX200 down 0.8%. Energy stocks were the hardest hit after Santos tumbled nearly 12% on news a $30 billion takeover bid collapsed. CSL slipped below $200 for the first time since 2019, while Origin Energy and CBA also weighed on the market. In contrast, Nuix surged on a major contract win and uranium miners bounced back. Meanwhile, a weaker-than-expected jobs report adds weight to the case for an RBA cut later this year. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Australian shares recovered modestly on Tuesday, with the ASX200 up about 0.25% as strength in energy, uranium and gold miners outweighed declines in Qantas, CSL and Super Retail Group. Commodity prices supported the resource sector, with gold hitting fresh record highs and oil rising on supply concerns. Investors remain cautious as they look ahead to a likely US rate cut later this week, as well as local jobs data, and Reserve Bank commentary. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

The ASX 200 rose 25 points in quiet trade to 8878 (0.3%) ahead of the Fed. Banks were mixed again, CBA down 0.3% and NAB and WBC up again. The Big Bank Basket flat at $284.23 (-0.1%). Wealth managers bounced slightly, MQG up 1.0% and NWL rising 1.5%. First day of trade for SOLDA the new look SOL/BKW entity. REITS slipped slightly, SCG down 0.5% and VCX off 0.8%. Industrials were mixed, retail better except SUL as its CEO was sacked, down 4.3%. CPU rallied 2.3% and REH rose 2.8%. Tech rose again, although WTC down 1.6% and XRO resumed the downtrend, off 0.6%. A long way down from the recent cap raise price. The All-Tech Index rose 0.7%. Resources remain the place to be. Iron ore miners rose, RIO up 1.9% with gold miners finding support, GMD up 0.7% and NEM up 0.9%. Lithium also in demand, MIN up 1.1% and LTR up 3.0%. Uranium stocks were roaring ahead, DYL up 9.2% and NXG rising 8.7%. PDN in a trading halt as it seeks to raise $300m in a placement and SPP. Oil stocks rose slightly in the second liners. Coal stocks also in demand, NHC rose 5.1% on good results, WHC up 1.9%.In corporate news, CSL fell another 1.3% as it announced a potential acquisition, SIG rallied 0.3% on Richard Murray's appointment as CFO.Nothing on the economic front locally. Asian markets better, Japan hitting new records up 0.5%, China down 0.4% and HK unchanged.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Applied to 50+ UX or Product jobs & still no interviews or offers? Get UX job search help.Welcome to the Career Strategy Podcast with Sarah Doody, a UX Designer & UX Researcher with 20 years of experience who founded the UX job search accelerator, Career Strategy Lab. She's been doing UX career coaching since 2017.Follow Sarah on: LinkedIn | YouTube | InstagramAfter 18 months of job searching with no results, Mariah was out of steam and questioning everything—until she joined Career Strategy Lab.In this Open House conversation, Sarah talks with Mariah, a UX researcher and experience strategist with a background in customer support and consulting. Mariah came to CSL after burning out from a year and a half of job searching while trying to relocate to Copenhagen. In this honest episode, she shares what finally helped her stop spinning, reconnect with herself, and gain the clarity, confidence, and support she'd been missing.Whether you're new to UX or deep in burnout, Mariah's story will remind you that it's not too late—and you don't have to figure it out alone.What You'll Learn in This Episode:✔️ What job searching for 18+ months taught Mariah about burnout and boundaries✔️ Why trying to “game the system” kept her stuck and exhausted✔️ How the Compass Sprint reconnected her to her voice, identity, and strengths✔️ Why the mindset calls inside CSL helped her finally feel like herself again✔️ How to balance personal and professional identity in your job search✔️ Her advice for perfectionists and overthinkers: take action, even when it's messyTimestamps:02:27 Mariah's Background and Career Journey04:21 Joining Career Strategy Lab: Initial Experiences08:09 Impact of Mindset Calls11:50 Tangible Actions and Career Roadmap18:43 Final Advice and Closing Remarks21:22 Podcast Outro and Additional Resources22:03 Special Message for Job Seekers⭐ Support the show! Leave a rating on Spotify or a review on Apple Podcasts to help more UX professionals find this podcast.

The ASX 200 fought back from earlier steeper losses to close down only 12 points at 8853 (0.1%). Banks held firm with ANZ copping a massive $240m fine from ASIC for dodgy conduct over the years. The Big Bank Basket fairly flat at $284.41 (). Wealth managers eased back, HUB fell 2.8% with NWL down 3.1% and SOL falling 5.2% on its last day of trade before merger. REITs generally firm with SGP up 0.6% and BWP up 2.2%. Healthcare remains in ICU with CSL falling another 1.6% and RMD down 1.4%. Industrials showed a tinge of green, SGH up 1.1% and ALL bouncing 2.2% after losses last week. In tech stocks, WTC rose 2.9% after Richard White disclosed a sale of a small parcel! XRO continued to trend lower again, down 0.6% with the All-Tech Index up 0.1%. In resources, Chinese data came in weaker than expected, BHP fell 0.6% with gold miners seeing some profit taking after a huge run in the last few weeks. EVN down 5.3% and NST falling 1.9%. GOR issued a production downgrade and fell 0.3%. Lithium stocks perked up, MIN up 3.2% and PLS being squeezed higher again, up 9.1%. VUL had a great run as shorts covered too, up 11.7%. Mixed in uranium with PDN up 1.8% and BOE flying up 7.9%. Oil and gas stocks showing limited gains, STO up 0.9%. In corporate news, EHL raced ahead on bid speculation. BUB has a new Chair. Nothing on the economic front locally. Chinese data came in weaker than expected prompting hopers of more stimulus. Asian markets pushed higher, Japan up 0.9%, China up 0.2% and HK unchanged.10-year yields at 4.27%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Wall Street recorded a positive, quiet session, with the S&P 500 and the Nasdaq reaching intraday highs. Markets in wait and see until the Federal Reserve's next policy meeting on September 17th. S&P 500 up 0.5%, Nasdaq up 0.9%. Dow rose throughout the first hour, then fell below its opening but recovered by the finish. Closed mid-range, up 49 points. Mixed sector performance. Growth sectors like Tech and Cyclicals led the gains, both rising 1.0% or more, boosted by Tesla and Alphabet rallies. Healthcare, Materials and Staples all showed weakness.ASX to rise. SPI futures up 43 points (+0.49%). CSL makes a move - Gold up 1%. Uranium in focus.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Ep. 329 What is Calling You? - Rev. Sue MillerBorn From the Sunday Service at the Center for Spiritual Living in Redding on 9-14-25

With Pfizer discontinuing Beqvez and BioMarin scaling back the commercial focus of Roctavian, the curative promise of hemophilia gene therapies is tempered by significant barriers that discourage widespread adoption. In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker speaks with Glenn Pierce, M.D., Ph.D., vice president of medical at the World Federation of Hemophilia, about the complexities behind these innovative therapies and the multifaceted reasons for their slow uptake. Pierce discusses the competitiveness of the current hemophilia gene therapy market, why Pfizer’s product couldn’t keep up, and the patient populations that risk being left behind. To learn more about the topics in this episode: As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio BioMarin downsizes Roctavian efforts but keeps hemophilia gene therapy for 3 markets See omnystudio.com/listener for privacy information.

With the ASX200 recovering some of September's lost ground this trading week, this week's wrap collates the key insights from Bell Potter's analysts that joined us this week for our webinar, Managing Market Volatility, where we unpacked the key highlights and lowlights of reporting season, discussed tactics to navigate volatility and provided outlook for FY26. You can view some of the highlights in this week's video, and below is the link to the full recording of the webinar in case you missed it live. Webinar link - Managing Market Volatility with Grady Wulff, Chris Savage, Rob Crookston and John Hester: https://youtu.be/vSm9tnwr0-I In this weekly wrap Grady covers: (0:30): how the ASX recovered some ground this trading week (1:30): Rob Crookston's outlook for FY26 & key reporting season findings (3:24): Chris Savage's analysis & tech valuations of FY25 reporting season(4:48): Chris' outlook for tech and two smaller names to watch in FY26(5:44): John Hester's findings from the healthcare sector this reporting season(6:52): how the local market performed over the last trading week(7:51): the most traded stocks and ETFs this week(8:22): economic calendar news items to look out for next week – China and US in focus.

The ASX 200 has finished the day down 25 points or 0.3% in a very quiet session. Close to what futures indicated as selling in Health Care increased and Banks failed to bounce. CSL continues to disappoint. Textbook case of bad results setting a new downtrend. PME managed to rally and finish up 0.6%. TLX back down 4.4% after looking encouraging yesterday. NEU worst, down 7.5% off lows. 4DX best. Up 18.9% as volatility returns. Big Four banks mixed but all down. CBA escaped most damage down 0.5%. ANZ worst down 1.6%. SOL down 3.3%. Stock market stocks mixed with GDG the standout again. Tech stayed flat from midday. WTC quiet. XRO and NXT stayed up. 360 down a touch.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you.If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 has finished the day down 22 points or 0.2%, trading in a narrow session as expected after not much of a US lead. Banks down, Resources slightly down. Technology stayed on top from midday. WTC, XRO gaining. 360, DDR and CAT best. Nasdaq futures slightly higher boosting sentiment. Health Care the only other sector to gain. CSL in the early stages of a V-shaped bounce. TLX staying in firm downtrend. The bottom not yet in sight. 4DX closing up 50%. Bringing the weekly move to 200% on more good news. REITs flat on the surface yet GDP and MGR managed modest gains. The sector as a whole not bouncing despite the 4.5bp drop in bond yields since Friday's close. Citi has said only to expect one more RBA rate cut this year.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you.If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

CSL 裁员3000人，而公司利润明明在上涨。 这是否由AI 引发？普通人如何保住饭碗？Morgans 亚洲业务主管深度解析，点击收听，并欢迎您在SBS中文社交媒体平台留言，表达您的观点。

Ep. 328 You are Worthy…Simply Because - Rev. Dr. Mary Michell From the Sunday Service at the Center for Spiritual Living in Redding on 9-7-25

What do seminary school, a dairy burn room, and running a global biotech powerhouse have in common? Paul Perreault. In this episode of The Authority Company Podcast, host Joe Pardavila sits down with Paul Perreault, former CEO of CSL and author of The Detour CEO, to explore how a non-linear path shaped his values-driven approach to leadership. Paul opens up about working 80-hour weeks in a restaurant, scrubbing burnt milk, and studying to become a priest—all before leading a multi-billion dollar company. He shares why being a generalist is underrated, how to separate identity from work, and what it really means to “add value” in life and business. Whether you're navigating your own professional pivot or leading a team, Paul's insights on humility, culture, and the myth of the corporate ladder are worth the listen.

Applied to 50+ UX or Product jobs & still no interviews or offers? Get UX job search help.Welcome to the Career Strategy Podcast with Sarah Doody, a UX Designer & UX Researcher with 20 years of experience who founded the UX job search accelerator, Career Strategy Lab. She's been doing UX career coaching since 2017.Follow Sarah on: LinkedIn | YouTube | InstagramWondering how to stand out in UX without burning out? Former technical recruiter Ellie shares her story of switching into product design—and how Career Strategy Lab helped her get her confidence back.In this episode, Sarah interviews Ellie, a former technical recruiter turned UX designer, who joined Career Strategy Lab while navigating new motherhood, burnout, and the unpredictable job market. Despite landing interviews, Ellie felt stuck—and knew she needed a structured, supportive way to rebuild confidence and stand out.You'll hear how she overcame perfectionism, reframed her job search, and built career habits that now extend beyond her portfolio and into her life.What You'll Learn in This Episode:✔️ Why Ellie left tech recruiting to pursue UX—and doesn't regret it✔️ What made her say “yes” to CSL (and why she wishes she joined sooner)✔️ How the Compass Statement gave her clarity and saved her time✔️ The unexpected life shifts that came from doing the work with intention✔️ Tips for breaking perfectionism and building habits that stick✔️ What it's like to join CSL while navigating new parenthood and burnoutTimestamps:00:00 Introduction to Career Strategy Lab00:38 Episode Overview and Open House Context02:23 Meet Ellie: From Technical Recruiter to Product Designer05:19 Ellie's Career Journey and CSL Experience09:16 The Impact of Career Strategy Lab18:47 Advice and Final Thoughts21:32 Conclusion and Next Steps⭐ Support the show! Leave a rating on Spotify or a review on Apple Podcasts to help more UX professionals find this podcast.

The guys destroy CSL and Reece’s WFH Excuse, Adir breaks down Site Minder’s huge surge, Qantas delivers a record result, Nvidia hits new highs but are grey skies looming, Blackbird’s Class of 2015, Sydney Outshines Dan Andrews’ Hellhole and KPop Rules. Thanks for listening! Join us on LinkedIn: https://www.linkedin.com/company/the-contrarians-with-adam-and-adir-podcast Subscribe on YouTube for all our video content: https://https://www.youtube.com/@ContrariansPodcast Follow us on Instagram: https://www.instagram.com/contrarianspod Follow us on TikTok: https://www.tiktok.com/@contrarianspodSee omnystudio.com/listener for privacy information.

Ep. 327 Love's Ascent - Rev. Sue MillerBorn From the Sunday Service at the Center for Spiritual Living in Redding on 8-31-25

Two years ago Mark purchased CSL. The share has not done well in that period. Mark goes through his thoughts on CSL, whether it still meets his original thesis, and evaluates whether the share deserves a place in his portfolio.You can find the full article here. A message from Mark and ShaniFor the past five years, we've released a weekly podcast to arm you with the tools to invest successfully. We've always strived to provide independent, thoughtful analysis, backed by the work of hundreds of researchers and professionals at Morningstar.We've shared our journeys with you, and you've shared back. We've listened to what you're after and created a companion for your investing journey. Invest Your Way is a book that focuses on the investor, instead of the investments. It is a guide to successful investing, with actionable insights and practical applications.The book is currently in presale which is an important time to build momentum. If anyone would like to support this project you can buy the book now. Thanks in advance!Purchase from Amazon or Purchase from BooktopiaTo submit any questions or feedback, please email mark.lamonica1@morningstar.com or leave us a voicemail to feature on the podcast here.Audio Producer and mixer: William Ton. Hosted on Acast. See acast.com/privacy for more information.

Audio roundup of selected biopharma industry content from Scrip over the business week ended August 22, 2025. In this episode: Madrigal regains MASH lead with EU Rezdiffra approval; Viking's obesity data scare investors; China assets lead GLP-1 deals; CSL and others restructure; and Indegene exec on DTP and MFN policies. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-T77LV22VANAL5GNPCC2YUVLZBE/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

The guys chat about CSL’s vaccine spin off and its share price disaster, just how good is Canva, Xero CEO’s lavish pay packet gets slammed by shareholders, Step One struggles to make a buck, RBA again fails basic understanding of how money works and Adam quizzes Adir on the world’s most valuable companies. Thanks for listening! Join us on LinkedIn: https://www.linkedin.com/company/the-contrarians-with-adam-and-adir-podcast Subscribe on YouTube for all our video content: https://https://www.youtube.com/@ContrariansPodcast Follow us on Instagram: https://www.instagram.com/contrarianspod Follow us on TikTok: https://www.tiktok.com/@contrarianspodSee omnystudio.com/listener for privacy information.

Ep. 326 The Turbulence of Love - Rev. Sue MillerBorn From the Sunday Service at the Center for Spiritual Living in Redding on 8-24-25

– RBA’s $1.2b renovation – Economic roundtable disappointment – CSL, James Hardie and Audinate hit for six – Qantas’ $90m fine and NAB’s $130m make-good – CBA’s AI SNAFUSee omnystudio.com/listener for privacy information.

澳洲最大的製藥公司 CSL 周二宣布，將在全球裁員 3,000 人，公司認為最新業績未達投資者理想預期，需重組「簡化業務」。目前市場是否擔心，在疫情紅利冷卻後,醫藥股或難以東山再起？

The Aussie market eased on Friday, snapping its run of record highs as the ASX 200 slipped around half a percent to just under 9,000 points. Healthcare stocks weighed heavily, with CSL plunging after its restructure plans, while James Hardie also disappointed. On the flipside, Zip surged after strong US growth, while NRW and Helia posted gains. Ingham’s and Guzman y Gomez tumbled on results, and Regis Resources pulled back despite a strong year. Attention now shifts to Jerome Powell’s keynote at Jackson Hole and a busy week of earnings ahead, with results due from Coles, Woolworths, Qantas, Wesfarmers, and NVIDIA. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

The ASX 200 ended modestly higher after a choppy session, with investors digesting profit results and awaiting a key speech from US Fed Chair Jerome Powell. Heavy losses in miners and healthcare, including further weakness in CSL, were offset by strong gains in the big banks. James Hardie slumped on weak US demand, while Breville and Iluka also disappointed. On the upside, Magellan, Stockland, Lottery Corp and Transurban all posted strong results and lifted sharply. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Applied to 50+ UX or Product jobs & still no interviews or offers? Get UX job search help.Welcome to the Career Strategy Podcast with Sarah Doody, a UX Designer & UX Researcher with 20 years of experience who founded the UX job search accelerator, Career Strategy Lab. She's been doing UX career coaching since 2017.Follow Sarah on: LinkedIn | YouTube | InstagramLaid off and wondering if you've “missed your shot”? This story will change how you think about career momentum.In this Open House conversation, Sarah sits down with Manny, a senior UX designer who transitioned into UX after a decade in graphic design and just landed a role at Fidelity. After getting laid off and spending weeks spinning his wheels, Manny joined Career Strategy Lab to bring clarity, structure, and confidence back to his job search.In this honest and insightful conversation, Manny shares what helped him rebuild momentum, how the Compass Sprint shaped everything from his resume to interviews, and why he wishes he'd joined sooner.What You'll Learn in This Episode:✔️ How Manny landed a UX role at Fidelity after being laid off✔️ The single most valuable CSL exercise (that he didn't expect)✔️ Why clarity leads to faster progress across your materials✔️ How the Compass Statement helped him shape his story and stand out✔️ Why applying early in your job search saves you time, money, and confidence✔️ How to make the most of CSL—whether you're employed or notTimestamps:02:28 Meet Manny: A UX Designer's Journey03:51 Navigating Job Search Challenges06:16 The Impact of Career Strategy Lab12:27 Advice for UX Job Seekers14:54 Conclusion and Final Thoughts15:07 Podcast Outro and Additional Resources15:47 Special Message for Job Seekers⭐ Support the show! Leave a rating on Spotify or a review on Apple Podcasts to help more UX professionals find this podcast.

Qantas has copped a record $90 million fine for its illegal sackings of staff…and more than half of the money is going straight to the union. CSL, the Aussie biotech, is cutting almost 3000 staff globally, as part of the biggest shake-up of the last decade. Soho House, the members club, is going private again after battling in the public markets for the past 4 years. _ Learn more about iShares by BlackRock here Download the free app (App Store): http://bit.ly/FluxAppStore Download the free app (Google Play): http://bit.ly/FluxappGooglePlay Daily newsletter: https://bit.ly/fluxnewsletter Flux on Instagram: http://bit.ly/fluxinsta Flux on TikTok: https://www.tiktok.com/@flux.finance —- The content in this podcast reflects the views and opinions of the hosts, and is intended for personal and not commercial use. We do not represent or endorse the accuracy or reliability of any opinion, statement or other information provided or distributed in these episodes.__ Issued by BlackRock Investment Management (Australia) Limited ABN 13 006 165 975, AFSL 230 523. Refer to FSG available on our website. Before making any investment decisions, you should assess whether the product or service is appropriate for you and read the PDS and TMD available at blackrock.com.au.See omnystudio.com/listener for privacy information.

SBS Finance Editor Ricardo Gonçalves speaks with Woodside Energy CEO Meg O'Neill and BHP CFO Vandita Pant following their profit results, while FTSE Russell Julia Lee goes through the day's market action including why investors slammed CSL.

One stock accounted for almost of the declines across the ASX today. Steve joins the podcast to reflect on the end to the recent winning streak bringing the first decline in a while. He discusses the imminent US rate cut decision, the Aussie sectors with healthcare seeing substantial declines amid CSL shares dropping more than 16%. Seek was one of the winners today following their latest results, and Steve looks to the day ahead with CBA set to go ex-dividend, and major US retail stocks expected to release their earnings data as the week continues. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

The market's run towards 9000 points was halted by a bad day for CSL, which lost 17% after announcing it would cut 3000 jobs.See omnystudio.com/listener for privacy information.

CSL has suffered its biggest single day fall on the market, dropping 17% and wiping $20 billion from the company’s value MARKET WRAP: ASX200: down 0.7% to 8,896 GOLD: $3,337/oz BITCOIN: $178,089 CURRENCY UPDATE: AUD/USD: 64.9 US cents AUD/GBP: 48.0 British pence AUD/EUR: 55 Euro cents AUD/JPY: 96 Yen AUD/NZD: 1.09 NZ dollars See omnystudio.com/listener for privacy information.

Wall Street held steady as investors brace for the Jackson Hole Symposium, while the US dollar climbed as Donald Trump hosted talks on Ukraine. Elsewhere, Private equity giant Thoma Bravo was reported to be in discussions to acquire software firm Dayforce, and the Trump administration is weighing a potential 10% stake in Intel. Solar stocks gained on the back of a favorable tax credit ruling, while US bonds rose as bets on a September rate cut remained intact. Back home, Aussie shares are set to retreat from record highs, with investors eyeing earnings results from Woodside Energy, BHP, and CSL. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Ep. 325 Soaring in Love - Lewanna Godinez From the Sunday Service at the Center for Spiritual Living in Redding on 8-17-25

Ep. 324 Love's Ascent - Rev. Lynn E. Fritz From the Sunday Service at the Center for Spiritual Living in Redding on 8-10-25

Ep. 323 The Launch of Love - Rev. Sue MillerBorn From the Sunday Service at the Center for Spiritual Living in Redding on 8-3-25

As the world's largest biotech partnering event took place in Boston in June, MTPConnect was there introducing an Australian delegation to the Boston ecosystem, hosting business events to drive international collaborations and leading the Australian Pavilion to highlight Australia's fast-growing life sciences sector to the international biotech industry.Our CEO Stuart Dignam was on the ground to find out why people are making the trip to BIO and what the buzz is all about. In this episode, Stuart speaks to Brent Owens, co-founder of Ballarat-based Vitrafy Life Sciences – a company pioneering cryopreservation technology and Brent Barnes, CEO and Manager Director of Adelaide-based Clever Culture Systems - inventor of APAS Independence, an intelligent microbiology culture plate reading technology that is revolutionising pharmaceutical lab work. These Australian start-ups have established a foothold in the US and are looking to expand and navigate the new tariff regime. Stuart also catches up with Professor Chris Molloy from the UK's Medicines Discovery Catapult to get his take on BIO and find out more about the BIOBridge initiative and why collaboration is key to solving the world's health challenges. For the support and partnership, MTPConnect would like to thank the state governments of NSW, Victoria, Queensland, Western Australia and South Australia, and the Department of Industry, Science and Resources, Austrade, CSIRO and AusBiotech.And thanks for the industry support from Moderna, Novartis, Australia & New Zealand, Cytiva, Sanofi, Arrotex Pharmaceuticals and Nutromics, and support for MTPConnect's Australian delegation site visit program from CSL and Global Pharma Solutions. 

Ep. 322 Going Deeper - Gary Lynn Floyd From the Sunday Service at the Center for Spiritual Living in Redding on 7-27-25

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has dropped an early-stage obesity asset, CT-173, citing lack of competitiveness. Novartis has entered into a drug discovery deal with Matchpoint Therapeutics, acquiring global rights on all molecules for several inflammatory diseases. AstraZeneca claims a Phase III win with its nanobody treatment for myasthenia gravis. Second-quarter earnings season is approaching, and biotechs to watch include Sarepta and others facing challenges in the biopharma industry. Genentech downsizes as priorities shift, and GSK's comeback for Blenrep is on pause as the FDA delays its decision. The FDA's lack of transparency has tarnished Sarepta's reputation after patient deaths triggered an FDA battle. Opportunities in the industry include roles like Quality Specialist at CSL and Clinical Research Physician at Eli Lilly and Company.

Applied to 50+ UX or Product jobs & still no interviews or offers? Get UX job search help.Welcome to the Career Strategy Podcast with Sarah Doody, a UX Designer & UX Researcher with 20 years of experience who founded the UX job search accelerator, Career Strategy Lab. She's been doing UX career coaching since 2017.Follow Sarah on: LinkedIn | YouTube | InstagramTired of vague AI tools that spit out generic resume rewrites and surface-level portfolio tips? Meet the smarter alternative.In this episode, Sarah shares the behind-the-scenes strategy behind Sage—the AI agent exclusively available inside Career Strategy Lab—and why it's already helping job seekers finish their resumes, portfolios, and LinkedIn profiles faster without sacrificing clarity or confidence.You'll learn why this tool is more than just a shortcut—it's a UX-informed, coach-trained experience designed to get you unstuck and back into momentum, 24/7.What You'll Learn in This Episode:✔️ The two problems most UX job seekers face: info overload + execution overwhelm✔️ Why most AI job search tools fail (and how Sage is different)✔️ How Sage is trained on CSL's proven curriculum and thousands of real conversations✔️ Why context-specific feedback beats ChatGPT every time✔️ How CSL members are using Sage to move faster and stop second-guessing✔️ The one mindset shift that will help you use AI effectively in your careerTimestamps:00:00 Introduction and Common Job Search Struggles00:46 Introducing Career Strategy Lab's AI Tools02:01 Why UX Professionals Struggle in Job Searches02:39 The Problems Our AI Tools Aim to Solve06:53 How Our AI Tools Work13:58 Demo of Sage, Our AI Agent27:51 Benefits of Using Sage29:36 Conclusion and Call to Action

Applied to 50+ UX or Product jobs & still no interviews or offers? Get UX job search help.Welcome to the Career Strategy Podcast with Sarah Doody, a UX Designer & UX Researcher with 20 years of experience who founded the UX job search accelerator, Career Strategy Lab. She's been doing UX career coaching since 2017.Follow Sarah on: LinkedIn | YouTube | InstagramFeel like you're doing everything “right” and still not getting anywhere? You might be saying yes to too much—and it's slowing you down.In this episode, Sarah shares how one of Steve Jobs' greatest strengths—his ability to say no—has shaped the design of Career Strategy Lab and her own career choices. You'll hear how saying no to shiny objects, distractions, and opportunities that seem exciting on the surface actually leads to deeper results, more momentum, and a better UX for job seekers inside CSL.Whether you're applying to every job that pops up, overcommitting to upskilling, or trying to be everything to everyone, this episode is a reminder that focus is a strategy—and saying no is a skill.What You'll Learn in This Episode:✔️ What Steve Jobs' product philosophy can teach you about your UX career✔️ How Sarah decides what to say no to in her business—and why it matters✔️ Why not doing “all the things” actually creates better outcomes for clients✔️ The trade-offs you're making every time you say yes✔️ How saying no led to CSL's newest AI tool + all-in-one experience✔️ 3 reflection questions to help you narrow your focus and move forwardTimestamps:01:50 Steve Jobs' Focus Strategy03:55 Applying Focus in My Career08:01 The Importance of Specialization11:47 Real-Life Examples of Saying No13:28 The Ripple Effect of Focus17:50 Final Thoughts and Career Advice20:07 Conclusion and How to Connect⭐ Support the show! Leave a rating on Spotify or a review on Apple Podcasts to help more UX professionals find this podcast.